Ensign Peak Advisors
NBIX icon

Ensign Peak Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Ensign Peak Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.7M Sell
175,946
-5,535
-3% -$821K 0.05% 259
2026
Q1 		$23.9M Buy
181,481
+14,174
+8% +$1.88M 0.04% 278
2025
Q4 		$23.7M Sell
167,307
-13,124
-7% -$1.9M 0.04% 270
2025
Q3 		$25.3M Buy
180,431
+9,648
+6% +$1.31M 0.04% 278
2025
Q2 		$21.5M Sell
170,783
-23,961
-12% -$2.75M 0.04% 303
2025
Q1 		$21.5M Buy
194,744
+21,050
+12% +$2.67M 0.04% 290
2024
Q4 		$23.7M Sell
173,694
-1,141
-0.7% -$141K 0.04% 290
2024
Q3 		$20.1M Sell
174,835
-97,778
-36% -$13.4M 0.04% 328
2024
Q2 		$37.5M Buy
272,613
+117,902
+76% +$16.2M 0.07% 207
2024
Q1 		$21.3M Buy
154,711
+82,103
+113% +$11.2M 0.04% 314
2023
Q4 		$9.57M Sell
72,608
-12,613
-15% -$1.45M 0.02% 451
2023
Q3 		$9.59M Sell
85,221
-10,632
-11% -$1.12M 0.02% 404
2023
Q2 		$9.04M Buy
95,853
+27,433
+40% +$2.68M 0.02% 442
2023
Q1 		$6.93M Buy
68,420
+16,115
+31% +$1.68M 0.02% 486
2022
Q4 		$6.25M Buy
52,305
+7,866
+18% +$921K 0.01% 508
2022
Q3 		$4.72M Sell
44,439
-17,036
-28% -$1.73M 0.01% 535
2022
Q2 		$5.99M Sell
61,475
-4,515
-7% -$417K 0.01% 490
2022
Q1 		$6.19M Sell
65,990
-5,862
-8% -$497K 0.01% 527
2021
Q4 		$6.12M Sell
71,852
-35,105
-33% -$3.23M 0.01% 606
2021
Q3 		$10.3M Sell
106,957
-2,322
-2% -$219K 0.02% 425
2021
Q2 		$10.6M Buy
109,279
+60,600
+124% +$5.81M 0.02% 417
2021
Q1 		$4.74M Sell
48,679
-125,879
-72% -$13.2M 0.01% 644
2020
Q4 		$16.7M Sell
174,558
-33,501
-16% -$3.24M 0.04% 344
2020
Q3 		$20M Buy
208,059
+76,370
+58% +$8.83M 0.05% 304
2020
Q2 		$16.1M Buy
131,689
+38,789
+42% +$4.29M 0.04% 336
2020
Q1 		$8.04M Sell
92,900
-17,948
-16% -$1.76M 0.03% 398
2019
Q4 		$11.9M Buy
+110,848
New +$11.6M 0.03% 391

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Ensign Peak Advisors's NBIX Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Neurocrine Biosciences (NBIX) stake by 3% in Q2 2026, selling an estimated $821K and leaving 175,946 shares worth $29.7M. The position accounts for 0.05% of the portfolio, ranked #259.

Ensign Peak Advisors first reported a position in NBIX in Q4 2019 and has held it in 27 quarters since. The position peaked at $37.5M in Q2 2024. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Ensign Peak Advisors held 175,946 shares of Neurocrine Biosciences worth $29.7M as of Q2 2026.
  • Ensign Peak Advisors sold 5,535 Neurocrine Biosciences shares in Q2 2026, an estimated $821K.
  • Neurocrine Biosciences made up 0.05% of Ensign Peak Advisors's portfolio in Q2 2026, its #259 holding.
  • Ensign Peak Advisors first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 27 quarters since.
  • Ensign Peak Advisors's Neurocrine Biosciences position peaked at $37.5M in Q2 2024.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.